

Domino Heck–Aza-Michael Reactions: A One-Pot, Sequential Three-Component Approach to 1,1-Dioxido-1,2-benzisothiazoline-3-acetic Acid

Alan Rolfe,^[a,b] Kyle Young,^[a,b] and Paul R. Hanson*^[a,b]

Keywords: Domino reactions / Sultams / Heck reaction / Aza-Michael reaction / Multicomponent reactions


The development of a new method for the synthesis of 1,1-dioxido-1,2-benzisothiazoline-3-acetic acid by a domino process is reported whereby a classical Heck reaction is coupled to an intramolecular aza-Michael reaction. Ultimately, this method has been expanded to a one-pot, sequential three-

component protocol to generate diverse benzofused γ -sultams from a range of commercially available α -bromobenzenesulfonyl chlorides, amines and Michael acceptors.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

Introduction

The development of facile methods to heterocyclic scaffolds is critical to the drug-discovery process.^[1] Cascade or domino reactions are highly efficient pathways that allow for the synthesis of complex molecules from simple substrates and encompass a variety of transformations such as Mannich and Robinson annulation reactions to name a few.^[2] Ultimately, domino strategies require compatibility of reagents with all products, along with efficient individual steps to afford an overall high yielding process. Several approaches have emerged that couple transition-metal-catalyzed reactions and classical protocols to achieve domino processes in a single one-pot operation.^[3] The Heck reaction is well suited in this regard revealing the original functionality of its olefinic partner for additional transformations. In particular, acrylates are ideal partners, because they can undergo facile Heck coupling, and still retain Michael accepting capabilities.^[4] Despite successes in this area, the existence of a domino process coupling Heck and aza-Michael methodologies as a means to generate new heterocycles is restricted to two examples in the literature, both limited by low yields and/or long reaction times.^[5] To the best of our knowledge, no examples of a domino Heck–aza-Michael approach towards the synthesis of sultams exist in the literature. Herein, we report the synthesis of 1,1-dioxido-1,2-benzisothiazoline-3-acetic acid by a domino process whereby a classical Heck reaction is coupled to an intramolecular aza-Michael reaction (HaM), ultimately resulting in a one-pot, sequential three-component protocol from commercially available starting materials (Scheme 1).^[6]



Scheme 1. Domino Heck–aza-Michael (HaM).

Compounds containing the sulfonamide moiety have gained wide popularity due to their extensive chemical and biological profiles.^[7] Sultams (cyclic sulfonamide analogs) have emerged as privileged structures in drug discovery due to their wide biological profile. A number of benzofused sultams have recently surfaced that display potent activity including anti-inflammatory,^[8] anti-malarial,^[9] anti-HIV^[10] and lipoxigenase inhibition (Figure 1),^[11] to name a few. Traditionally, syntheses of sultams have been accomplished by classical cyclization protocols such as Friedel–Craft,^[12] dianion,^[13] [3+2] cycloadditions,^[14] and Diels–Alder reactions.^[15] Recently, however, a number of transition-metal-catalyzed approaches to sultams have emerged, including use of ring-closing metathesis (RCM),^[16] Heck,^[17] as well as Au-,^[18] Cu-,^[19] and Rh-catalyzed^[20] cyclizations. Interest in the development of new routes to structurally diverse heterocycles has led to the titled domino process, which is now reported.^[21]

[a] Department of Chemistry, University of Kansas, 1251 Wescoe Hall Drive, Lawrence, KS 66045-7582, USA

[b] The Center for Chemical Methodologies and Library Development at The University of Kansas (KU-CMLD), 1501 Wakarusa Drive, Lawrence, KS 66047, USA

Supporting information for this article is available on the WWW under <http://www.eurjoc.org> or from the author.





Figure 1. Representative biologically active sultams.

Results and Discussion

Initial reaction screening in this study was conducted on preformed sulfonamide **1** where a variety of bases and Pd⁰-sources were studied for the synthesis of sultam **2** (Table 1). Sulfonamide **1** (0.1 M in DMF) was heated at 110 °C in the presence of methyl acrylate, Pd⁰-catalysts and base for 14 h. Under these conditions, sulfonamide **1** underwent facile Heck coupling, followed by intramolecular aza-Michael cyclization,^[22] to afford **2** in an overall domino process. These preliminary studies showed that the combination of Et₃N with either Pd(OAc)₂/PPh₃ or Pd₂(dba)₃·CHCl₃ gave the best results, with the presence of additive essential for high yields (Table 1, Entry 1 vs. Entries 5/6). Moreover, it was found that use of Pd₂(dba)₃·CHCl₃ complex was preferred over the use of Pd(OAc)₂/PPh₃ which produced reaction mixtures containing Pd-mirror. Comparable results were achieved using microwave irradiation, however, a higher catalyst load (10–20 mol-%) was required (Table 1, Entries 7/8).


In the initial optimization phase, wet Bu₄NCl was utilized to promote the domino process. Further investigation into this effect revealed that anhydrous Bu₄NCl promoted the reaction, however with diminished efficiency (Table 2). On further study of this empirical result, we found that the addition of 10 mol-% of H₂O to the reaction enhanced the yield when using either anhydrous Bu₄NCl or Bu₄NI. Though a true understanding of how the addition of water enhances yield is not entirely reached, it has been documented that higher yields can be achieved for Pd-catalyzed reactions that use water as a co-solvent.^[23]

The scope of this chemistry was next examined with an array of commercially available Michael acceptors, yielding products bearing a variety of functional handles (Table 3).

Table 1. Domino Heck–aza–Michael.^[a]


Entry	Catalyst	Base	Additive	% Conv. ^[b]
1	Pd(OAc) ₂ /PPh ₃	Et ₃ N	–	34
2	Pd(OAc) ₂ /PPh ₃	CS ₂ CO ₃	–	15
3	PdCl ₂ (PPh) ₃	CS ₂ CO ₃	–	13
4	Pd ₂ (dba) ₃ ·CHCl ₃	Et ₃ N	–	35
5	Pd(OAc) ₂ /PPh ₃	Et ₃ N	Bu ₄ NCl	91
6	Pd ₂ (dba) ₃ ·CHCl ₃	Et ₃ N	Bu ₄ NCl	95
7	Pd(OAc) ₂ /PPh ₃	Et ₃ N	–	94 ^[c]
8	Pd(OAc) ₂ /PPh ₃	Et ₃ N	Bu ₄ NCl	95 ^[d]

[a] Reaction conditions: **1** (0.12 mmol), Pd (2 mol-%), methyl acrylate (0.36 mmol), base (0.36 mmol) in DMF at 110 °C for 14 h. [b] Conversion by G.C. [c] Pd(OAc)₂ (20 mol-%), PPh₃ (40 mol-%) in microwave 110 °C for 2 h. [d] Pd(OAc)₂ (10 mol-%), PPh₃ (20 mol-%) in microwave 110 °C for 2 h.


Table 2. Domino Heck–aza–Michael.^[a]


Entry	Additive	Water [mol-%]	% Conv. ^[b]
1	–	–	35
2	Bu ₄ NCl	–	72
3	Bu ₄ NCl	10 mol-%	95
4	Bu ₄ NI	–	68
5	Bu ₄ NI	10 mol-%	94

[a] Reaction conditions: **1** (0.12 mmol), Pd (2 mol-%), methyl acrylate (0.36 mmol), Et₃N (0.36 mmol) and Bu₄NCl (0.12 mmol) in DMF at 110 °C for 14 h. [b] Conversion by G.C.

In the presence of Pd₂(dba)₃·CHCl₃, several Michael acceptors were subjected to the reaction conditions, affording the desired compounds in good to high yield (Table 3, Entries 1–4). Attempts utilizing methyl methacrylate were unsuccessful, while the use of acrylonitrile and dimethyl vinyl phosphonate gave low yields. Of notable importance is the successful use of both acrylic acid and acrylamide to yield the corresponding sultam bearing carboxylic or amide handles, which are primed for further diversification.


The use of the Heck–aza–Michael reaction in a one-pot, sequential three-component process was next demonstrated. In this protocol, a variety of α-bromobenzenesulfonyl chlorides were coupled with a range of aromatic, cyclic and alkylamines to yield intermediate sulfonamides. After two hours, Et₃N, Bu₄NCl, Pd₂(dba)₃·CHCl₃ and the corresponding Michael acceptor were added to the reaction mix-

Table 3. Scope of possible Michael acceptors.^[a]


Entry	R	Product	% Yield ^[b]
1	OMe	2	95
2	OEt	3	92
3	OH	4	94
4	Me	5	79
5	NH ₂	6	81

[a] Reaction conditions: **1** (0.12 mmol), Pd₂(dba)₃·CHCl₃ (2 mol-%), methyl acrylate (0.36 mmol), Bu₄NCl (0.12 mmol) in DMF at 110 °C for 14 h. [b] Isolated yields.

ture, which was subsequently heated to 110 °C and subjected to workup after 14 h.^[24] A small subset of 1,1-dioxido-1,2-benzisothiazoline-3-acetic acid was made using this one-pot protocol (Table 4). Reactions were typically carried out on the 0.27 mmol scale, affording products in good isolated yields (79–90%).^[25]


Table 4. Demonstration of a one-pot domino protocol.^[a]


Entry	R ¹	R ²	R ³	Product	% Yield ^[b]
1	H	<i>c</i> -C ₅ H ₉	Me	7	74
2	H	<i>c</i> -C ₆ H ₁₁	OH	8	86
3	4-F	Bn	OEt	9	84
4	4-F	C ₈ H ₁₇	OH	10	90
5	H	4-ClPh	OEt	11	81
6	4-F	<i>c</i> -C ₆ H ₁₁	OH	12	84
7	H	4-MeOPh	OMe	13	84

[a] Reaction conditions: **1** (0.12 mmol), Pd₂(dba)₃·CHCl₃ (2 mol-%), methyl acrylate (0.36 mmol), Bu₄NCl (0.12 mmol) in DMF at 110 °C for 14 h. [b] Isolated yields.

Further application of this multicomponent protocol was demonstrated utilizing the commercially available 2,5-dibromosulfonyl chloride **15** (Table 5). In this method, 1,1-dioxido-1,2-benzisothiazoline-3-acetic acid **16–19** possessing both saturated and unsaturated side chains were generated in good to excellent yields (85–93%). In all cases the intramolecular aza-Michael reaction proceeded with high yield forming the desired γ -sultam.


The versatility of this protocol was next examined with a variety of other attractive substrates (**20–22**, Scheme 2). When submitted to the domino Heck–aza-Michael procedure, amide **20** remained unreacted, which further sub-

Table 5. Application of domino HAM protocol with **15**.^[a]


Entry	R ¹	R ²	Product	% Yield ^[b]
1	4-MeOPh	Me	16	88
2	C ₈ H ₁₇	OMe	17	84
3	4-MeOPh	OMe	18	93
4	2-MeOBn	OEt	19	86

[a] Reaction conditions: **1** (0.12 mmol), Pd₂(dba)₃·CHCl₃ (2 mol-%), methyl acrylate (0.36 mmol), Bu₄NCl (0.12 mmol) in DMF at 110 °C for 14 h. [b] Isolated yields. Compounds purified by mass-directed fractionation.


stantiates the aforementioned amide studies by Dyker and coworkers.^[5b,26] In addition to **20**, sulfonamide derivatives **21** and **22** were subjected to this protocol and, to our surprise, yielded only unreacted starting material. A plausible explanation for the unreactive cases involving sulfonamides **21** and **22** is the possibility of the free NH coordinating to palladium after the oxidative addition step and deactivating it for further chemistry.



Scheme 2.

In order to further probe the results shown in Scheme 2, *N*-(*o*-bromobenzyl)-2-bromobenzenesulfonamide (**23**), possessing both electron-poor and electron-rich bromoaryl moieties, was assembled and subjected to the domino Heck–aza-Michael conditions. In theory, this reaction can produce two possible products, **24** and **25**, depending on which Heck–aza-Michael pathway is operative. According to the data presented in Table 4, we would expect an initial facile oxidative addition of Pd⁰ at the more electron-deficient aryl bromide. In the case of **23**, this would be the bromide position *ortho* to the sulfonamide. Following the initial Heck addition, a facile aza-Michael reaction pro-

ceeds forming sultam **24**. A second Heck reaction then proceeds on the remaining aryl bromide since no free NH is present to deactivate the Pd⁰ (as in the case of **21** and **22**), resulting in the formation of only **24** (Scheme 3). When **23** was submitted to the standard HaM reaction conditions, one sole product was isolated as predicted along with starting material. Despite inconclusive NMR spectroscopic data due to the similar characteristics of **24** and **25**, results discussed have allowed for tentative assignment of sultam **24** as the isolated product.



Scheme 3.

In addition to the aforementioned biologically active sultams outlined in Figure 1,^[8–11] a number of related 1-oxoisindol-3-acetamide derivatives have been reported to possess potent sedative-hypnotic activity, and are NHE1 inhibitors as well as allosteric modulators of glucokinase (Figure 2).^[27]





Figure 2. Biologically active 1-oxoisindol-3-acetamides.



This promising bioactivity prompted use of the titled protocol to generate the analogous sultam derivatives in a one-pot procedure. The corresponding sulfonamide **26** and acrylamide **27** were thus generated in situ, followed by combination and submission to the domino HaM reaction conditions (Scheme 4). In the case of **28**, none of the desired

product was isolated from the reaction, only the product resulting from simple Heck reaction was observed in the crude mixture. Despite the utilization of a variety of both 1° and 2° amines, none of the desired sultam products were isolated. A plausible explanation is that the corresponding acrylamides are poorer Michael acceptors in comparison to their acrylate counterparts, further demonstrating how subtle electronic effects are operative in these systems.



Scheme 4.

To circumvent this problem, the sultam product derived from use of acrylic acid was coupled with the corresponding amine utilizing a high-load, soluble polymeric EDC variant OACC, derived from ring-opening metathesis polymerization (ROMP) (Scheme 5).^[28] To this effect, some 1,1-dioxido-1,2-benzisothiazoline-3-acetamide derivatives **29–31** bearing both saturated and aromatic side chains were synthesized. This was accomplished by a one-pot protocol whereby the corresponding sultam acid was generated, followed by OACC coupling with the corresponding amine.



Scheme 5.

As previously discussed, the formation of the sultam carboxylic acids requires the use of excess acrylic acid. This excess reagent itself can undergo coupling with the free amine to form the corresponding amide. To circumvent this

problem, the crude mixture was concentrated in situ to remove the excess acrylic acid. This is followed by resolution and formation of the corresponding amide by coupling utilizing $^{20}\text{OACC}_{50}$.^[29] Attempts to develop a “true” one-pot process starting from the corresponding sulfonamide were investigated. However, it was discovered that lowering the equivalents of acrylic acid from 3 to 1–1.5 significantly reduced the amount of cyclic acid formed and hence the amount of corresponding amide isolated.

Conclusions

In conclusion, a new method has been developed for the rapid synthesis of 1,1-dioxido-1,2-benzisothiazoline-3-acetic acid via a domino Heck–aza-Michael reaction. Expansion of the method to a one-pot, sequential three-component protocol to generate diverse benzofused sultams from commercially available α -bromobenzenesulfonyl chlorides, amines and Michael acceptors has been accomplished. This method has been utilized to synthesize a small demonstration library of 1,1-dioxido-1,2-benzisothiazoline-3-acetic acids bearing both saturated and unsaturated side chains. With this method in hand, a number of sultam derivatives of bioactive related isoindol-1-one amides were synthesized in a one-pot manner utilizing a ROMP-derived coupling reagent OACC. All of the compounds reported are currently undergoing broad biological screening through the NIH Molecular Library Screening Network (NIH-MLSCN) and the results will be reported in due course.

Experimental Section

General Procedures: All air- and moisture-sensitive reactions were carried out in flame- or oven-dried glassware under argon using standard gastight syringes, cannulas, and septa. Stirring was achieved with oven-dried, magnetic stir bars. CH_3CN was purified by passage through the Solv-Tek purification system employing activated Al_2O_3 .^[30] Et_3N was purified by passage over basic alumina and stored over KOH. Flash column chromatography was performed with SiO_2 from Sorbent Technology (30930M-25, Silica Gel 60A, 40–63 μm). Thin-layer chromatography was performed on silica gel 60F254 plates (EM-5717, Merck). Deuterated solvents were purchased from Cambridge Isotope laboratories. ^1H and ^{13}C NMR spectra were recorded with a Bruker DRX-400 NMR spectrometer operating at 400 MHz, 100 MHz, or 162 MHz, respectively; or a Bruker Avance operating at 500 MHz or 125 MHz, respectively. High-resolution mass spectrometry (HRMS) and FAB spectra were obtained in one of two manners: (i) on a VG Instrument ZAB double-focusing mass spectrometer and (ii) on a LCT Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).

***N*-Benzyl-2-bromobenzenesulfonamide (1):** Into a flame-dried flask under argon was added benzylamine (1.87 mL, 17.2 mmol) and dry CH_2Cl_2 (36 mL). Et_3N (4.35 mL, 31.2 mmol) was added and the reaction flask stirred at r.t for 15 min at which time *N*-benzyl-2-bromobenzene (4.0 g, 15.6 mmol) was added and the reaction mixture stirred for 2 h. The crude reaction mixture was concentrated and the resulting slurry was suspended in EtOAc (20 mL). The organic salts were removed by filtration and the solvent removed under reduced pressure. Flash chromatography (EtOAc/hexane, 1:1)

provided 5.02 g (98% yield) of the title compound as a white solid, m.p. 93–96 °C. FTIR (neat): $\tilde{\nu}$ = 3319, 1409, 1332, 1253, 1163 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 8.12 (dd, J = 7.8, 1.8 Hz, 1 H), 7.69 (dd, J = 7.8, 1.2 Hz, 1 H), 7.44 (dt, J = 7.6, 1.26 Hz, 1 H), 7.39 (dt, J = 5.6, 1.8 Hz, 1 H), 7.27–7.25 (m, 3 H), 7.18–7.23 (m, 2 H), 5.41–5.43 (m, 1 H), 4.10 (d, J = 6.2 Hz, 2 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 138.7, 135.6, 135.0, 133.7, 131.4, 128.7, 128.2, 128.0, 127.6, 119.7, 47.5 ppm. HRMS calculated for $\text{C}_{13}\text{H}_{12}\text{BrNO}_2\text{SNa}$ [$M + \text{Na}$] 347.9670; found 347.9700 (TOF MS ES+).

Methyl (2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)-acetate (2): Into a microwave vial was added **1** (39.1 mg, 0.12 mmol), Et_3N (50 μL , 0.36 mmol), $\text{Pd}(\text{OAc})_2$ (20 mol-%, 5.4 mg, 0.024 mmol), PPh_3 (40 mol-%, 12.6 mg, 0.048 mmol) and CH_3CN (0.6 mL). After stirring for 5 min, methyl acrylate (32 μL , 0.36 mmol) was added and the reaction placed in the microwave oven at 120 °C for 2 h. Then the reaction was concentrated under reduced pressure and purified using flash chromatography (hexane/EtOAc, 6:4) to provide 37.7 mg (95%) of the title compound as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1735, 1294, 1172 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.85 (d, J = 7.2 Hz, 1 H), 7.52–7.63 (m, 2 H), 7.42 (d, J = 7.2 Hz, 1 H), 7.28–7.36 (m, 5 H), 4.83 (t, J = 6.0 Hz, 1 H), 4.61 (d, J = 15.6 Hz, 1 H), 4.49 (d, J = 15.6 Hz, 1 H), 3.59 (s, 3 H), 2.86 (dd, J = 16.3, 5.4 Hz, 1 H), 2.70 (dd, J = 16.3, 6.7 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.5, 137.3, 135.3, 132.9, 131.0, 130.3, 129.5, 128.8, 128.4, 128.0, 124.1, 121.4, 119.5, 57.0, 52.0, 46.6, 38.9 ppm. HRMS calculated for $\text{C}_{17}\text{H}_{18}\text{NO}_4\text{S}$ [$M + \text{H}$]⁺ 332.0956; found 332.0958 (TOF MS EI⁺).

General Procedure (A) for the Synthesis of 1,1-Dioxido-1,2-benzisothiazoline-3-acetic Acid Derivatives Using a Range of Michael Acceptors from 1: Into a 1-dram vial was added **1** (40 mg, 0.12 mmol), Et_3N (51 μL , 0.36 mmol), Bu_4NCl (30 mg, 0.12 mmol), $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2 mol-%, 2.5 mg, 0.0024 mmol) and dry DMF (1.22 mL). After stirring for 5 min at room temp., Michael acceptor (0.36 mmol) was added and the reaction vial was placed immediately into a preheated reaction block. The reaction mixture was stirred at 110 °C for 14 h after which time the reaction was cooled and concentrated under reduced pressure. The crude product was purified using flash chromatography (hexane/EtOAc, 6:4).

Ethyl (2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)-acetate (3): Prepared using general method (A) with ethyl acrylate (39.9 μL , 0.366 mmol) to yield 38 mg of **3** (92%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 2361, 1733, 1290, 1172 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.84 (dd, J = 6.9, 1.2 Hz, 1 H), 7.53–7.60 (m, 2 H), 7.43 (d, J = 7.2 Hz, 2 H), 7.30–7.38 (m, 4 H), 4.82 (t, J = 6.1 Hz, 1 H), 4.62 (d, J = 15.6 Hz, 1 H), 4.52 (d, J = 15.6 Hz, 1 H), 4.03–4.06 (m, 2 H), 2.86 (dd, J = 16.3, 5.2 Hz, 1 H), 2.70 (dd, J = 16.3, 3.6 Hz, 1 H), 1.14 (t, J = 5.6 Hz, 3 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.0, 137.3, 135.3, 134.6, 132.8, 129.5, 128.7, 128.4, 128.0, 124.18, 121.40, 61.1, 57.0, 46.4, 39.0, 13.9 ppm. HRMS calculated for $\text{C}_{18}\text{H}_{19}\text{NO}_4\text{SNa}$ [$M + \text{Na}$]⁺ 368.0932; found 368.0930 (TOF MS EI⁺).

(2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetic Acid (4): Prepared using general method (A) with acrylic acid (25.0 μL , 0.366 mmol) to give 36 mg of **4** (94%) as a white solid, m.p. 120–122 °C. FTIR (neat): $\tilde{\nu}$ = 2923 (br), 1712, 1290, 1170, 1130 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.84 (d, J = 7.2 Hz, 1 H), 7.55–7.62 (m, 2 H), 7.38–7.42 (m, 3 H), 7.27–7.34 (m, 3 H), 4.82 (t, J = 5.4 Hz, 1 H), 4.62 (d, J = 15.6 Hz, 1 H), 4.51 (d, J = 15.6 Hz, 1 H), 2.91 (dd, J = 16.6, 5.0 Hz, 1 H), 2.70 (dd, J = 16.6, 6.9 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 174.8, 137.0, 135.0, 134.6, 133.0, 129.6, 128.8, 128.5, 128.1, 124.16, 121.49, 56.6, 46.7,

38.6 ppm. HRMS calculated for $C_{16}H_{16}NO_4S$ $[M + H]^+$ 318.0800; found 318.0817 (TOF MS EI^+).

1-(2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)propane-2-one (5): Prepared using general method (A) with methyl vinyl ketone (25.0 μ L, 0.366 mmol) to give 30 mg of **5** (79%) as a clear oil. FTIR (neat): $\tilde{\nu}$ = 1716, 1454, 1292, 1172, 1132 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 7.83 (m, 1 H), 7.51–7.58 (m, 2 H), 7.40 (d, J = 7.2 Hz, 2 H), 7.25–7.36 (m, 4 H), 4.98 (t, J = 5.9 Hz, 1 H), 4.56 (d, J = 14.7 Hz, 1 H), 4.42 (d, J = 15.6 Hz, 1 H), 2.97 (dd, J = 18.0, 5.6 Hz, 1 H), 2.77 (dd, J = 18.0, 6.3 Hz, 1 H), 1.90 (s, 3 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 205.4, 138.1, 135.8, 134.6, 132.95, 129.3, 128.7, 128.5, 127.9, 124.2, 121.3, 56.3, 48.2, 30.27 ppm. HRMS calculated for $C_{17}H_{17}NO_3SNa$ $[M + Na]^+$ 338.0827 found 338.0800 (TOF MS EI^+).

(2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetamide (6): Prepared using general method (A) with acrylamide (26 mg, 0.366 mmol) to yield 31 mg of **6** (81%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 1685, 1450, 1295, 1172, 1128 cm^{-1} . 1H NMR (500 MHz, $[D_4]MeOD$): δ = 7.81 (d, J = 7.7 Hz, 1 H), 7.65 (t, J = 7.5 Hz, 1 H), 7.59 (t, J = 7.2 Hz, 1 H), 7.51 (d, J = 7.7 Hz, 1 H), 7.47 (d, J = 7.3 Hz, 2 H), 7.28–7.38 (m, 3 H), 4.92 (t, J = 6.6 Hz, 1 H), 4.87 (br. s, 2 H), 4.64 (d, J = 15.6 Hz, 1 H), 4.50 (d, J = 15.6 Hz, 1 H), 2.84 (dd, J = 15.1, 6.1 Hz, 1 H), 2.61 (dd, J = 15.1, 7.0 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, $[D_4]MeOD$): δ = 174.8, 139.7, 137.5, 136.3, 134.6, 131.2, 130.3, 130.2, 130.1, 129.1, 59.5, 48.1, 41.6 ppm. HRMS calculated for $C_{16}H_{17}N_2O_3S$ $[M + H]^+$ 317.0960 found 317.0932 (TOF MS EI^+).

General Procedure (B) for the Synthesis of 1,1-Dioxido-1,2-benzisothiazoline-3-acetic Acid Derivatives: Into a 1-dram vial was added amine (0.273 mmol), Et_3N (0.547 mmol) and dry DMF (0.59 mL) and reaction mixture was stirred at r.t. for 15 min. Then, α -bromobenzenesulfonyl chlorides (0.273 mmol) were added and the reaction mixture was stirred for 2 h. To the reaction vial was added Et_3N (76 μ L, 0.548 mmol), Bu_4N (74.5 mg, 0.273 mmol), $Pd_2(dba)_3 \cdot CHCl_3$ (2 mol-%, 25.6 mg, 0.0056 mmol) and dry DMF (1.4 mL). After stirring for 5 min at room temp., Michael acceptor (0.819 mmol) was added and the reaction vial was placed immediately into a preheated reaction block. The reaction mixture was stirred at 110 $^{\circ}C$ for 14 h after which time the reaction was cooled and concentrated under reduced pressure. The crude was purified using flash chromatography (hexane/ $EtOAc$, 6:4).

1-(2-Cyclopentyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)propane-2-one (7): Prepared using general method (B) using benzenesulfonyl chloride, cyclopentylamine and methyl vinyl ketone to afford 52 mg of **7** (76%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1714, 1294, 1168 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 7.67 (d, J = 7.1 Hz, 1 H), 7.40–7.51 (m, 2 H), 7.32 (d, J = 7.6 Hz, 1 H), 5.02 (dd, J = 8.7, 3.7 Hz, 1 H), 3.15 (dd, J = 17.9, 5.7 Hz, 1 H), 2.86 (dd, J = 17.9, 7.6 Hz, 1 H), 2.11 (s, 3 H), 1.92–1.98 (m, 2 H), 1.64–1.75 (m, 4 H), 1.51–1.54 (m, 2 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 206.3, 139.3, 135.9, 132.8, 130.2, 129.7, 124.5, 121.1, 57.6, 55.3, 48.7, 31.0, 30.85, 28.9, 24.1, 22.7 ppm. HRMS calculated for $C_{15}H_{23}N_2O_3S$ $[M + NH_4]^+$ 311.1429; found 311.1446 (TOF MS EI^+).

(2-Cyclohexyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetic Acid (8): Prepared using general method (B) using α -bromobenzenesulfonyl chloride, cyclohexylamine and acrylic acid to yield 76 mg of **8** (86%) as a white solid, m.p. 121–124 $^{\circ}C$. FTIR (neat): $\tilde{\nu}$ = 2933, 2856, 1712, 1288, 1170 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 9.08–9.48 (br. s, 1 H), 7.74 (d, J = 7.6 Hz, 1 H), 7.57 (td, J = 7.5, 1.0 Hz, 1 H), 7.51 (t, J = 7.5 Hz, 1 H), 7.46 (d, J = 7.6 Hz, 1 H), 5.06 (dd, J = 8.1, 4.2 Hz, 1 H), 3.58–3.64 (m, 1 H),

3.08 (dd, J = 16.5, 4.2 Hz, 1 H), 2.84 (dd, J = 16.5, 8.1 Hz, 1 H), 1.94–2.04 (m, 4 H), 1.79–1.85 (m, 2 H), 1.59–1.68 (m, 2 H), 1.28–1.36 (m, 2 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 173.4, 136.4, 130.9, 127.5, 122.2, 119.0, 54.6, 52.8, 38.8, 30.3, 28.2, 24.1, 23.9, 23.4 ppm. HRMS calculated for $C_{15}H_{23}N_2O_4S$ $[M + NH_4]^+$ 327.1379; found 327.1399 (TOF MS EI^+).

Ethyl (2-Benzyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetate (9): Prepared using general method (B) using, 4-fluoro-2-bromobenzenesulfonyl chloride, benzylamine and ethyl acrylate to afford 92 mg of **9** (84%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1731, 1593, 1475, 1298, 1174 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 7.82 (dd, J = 8.6, 4.8 Hz, 1 H), 7.40–7.42 (m, 2 H), 7.30–7.36 (m, 3 H), 7.22–7.26 (m, 1 H), 7.09 (dd, J = 8.4, 2.1 Hz, 1 H), 4.78 (dd, J = 6.8, 6.7 Hz, 1 H), 4.60 (d, J = 15.6 Hz, 1 H), 4.48 (d, J = 15.6 Hz, 1 H), 4.02–4.10 (m, 2 H), 2.86 (dd, J = 16.4, 4.9 Hz, 1 H), 2.68 (dd, J = 16.4, 7.1 Hz, 1 H), 1.15 (t, J = 7.2 Hz, 3 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 167.9, 164.5 (d, J_{C-F} = 250.5 Hz), 138.6, 133.1, 127.2, 126.7, 126.4, 126.1, 121.7, 115.6, 109.9, 59.3, 54.7, 44.7, 36.7, 12.0 ppm. HRMS calculated for $C_{18}H_{22}FN_2O_4S$ $[M + NH_4]^+$ 381.1284; found 381.1295 (TOF MS EI^+).

(2-Octyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetic Acid (10): Prepared using general method (B) using 4-fluoro-2-bromobenzenesulfonyl chloride, octylamine and acrylic acid to yield 87 mg of **10** (90%) as a pale yellow solid, m.p. 123–127 $^{\circ}C$. FTIR (neat): $\tilde{\nu}$ = 2927, 2856, 1714, 1593, 1475 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 9.02–9.16 (br. s, 1 H), 7.79 (dd, J = 8.6, 4.7 Hz, 1 H), 7.24–7.26 (m, 1 H), 7.16 (dd, J = 8.3, 2.0 Hz, 1 H), 4.86 (m, 1 H), 3.30 (t, J = 15.3 Hz, 2 H), 3.06 (dd, J = 21.6, 4.7 Hz, 1 H), 2.83 (dd, J = 16.9, 7.4 Hz, 1 H), 1.66–1.75 (m, 2 H), 1.23–1.39 (m, 10 H), 0.85 (t, J = 6.8 Hz, 2 H). ^{13}C NMR (125 MHz, $CDCl_3$): δ = 173.5, 163.3 (d, J_{C-F} = 254.9 Hz), 138.4, 129.1, 121.8, 115.7, 109.7, 54.8, 41.8, 36.7, 29.8, 27.2, 26.1, 25.0, 20.7, 12.16 ppm. HRMS calculated for $C_{17}H_{28}FN_2O_4S$ $(M + NH_4)^+$ 375.1754; found 375.1769 (TOF MS EI^+).

Ethyl (4-Chlorophenyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetate (11): Prepared using general method (B) using 2-bromobenzenesulfonyl chloride, 4-chlorobenzylamine and ethyl acrylate to afford 73 mg of **11** (81%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1730, 1294, 1172 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 7.77 (d, J = 7.1 Hz, 1 H), 7.47–7.56 (m, 2 H), 7.30–7.34 (m, 3 H), 7.25 (d, J = 8.5 Hz, 2 H), 4.77 (t, J = 5.9 Hz, 1 H), 4.48 (q, J = 15.9 Hz, 2 H), 3.98–4.06 (m, 2 H), 2.78 (dd, J = 16.4, 5.8 Hz, 1 H), 2.66 (dd, J = 16.4, 6.2 Hz, 1 H), 1.09 (t, J = 7.2 Hz, 3 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 170.0, 137.1, 134.6, 134.1, 133.1, 133.0, 129.8, 129.2, 128.7, 124.1, 121.4, 61.2, 57.3, 46.2, 39.4, 14.2 ppm. HRMS calculated for $C_{18}H_{19}ClNO_4S$ $[M + H]^+$ 380.0723; found 380.0739 (TOF MS EI^+).

(2-Cyclohexyl-6-fluoro-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl)acetic Acid (12): Prepared using general method (B) using 4-fluoro-2-bromobenzenesulfonyl chloride, cyclohexylamine and acrylic acid to yield 65 mg of **12** (84%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 2935, 1718, 1288, 1172, 1122 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): δ = 7.73–7.76 (m, 1 H), 7.17–7.30 (m, 3 H), 5.01–5.08 (m, 1 H), 3.62 (t, J = 11.9 Hz, 1 H), 3.10 (d, J = 16.8 Hz, 1 H), 2.86 (dd, J = 16.8, 8.5 Hz, 2 H), 2.04 (d, J = 11.9 Hz, 1 H), 1.95 (d, J = 11.6 Hz, 1 H), 1.84 (t, J = 15.0 Hz, 1 H), 1.58–1.68 (m, 3 H), 1.30–1.38 (dd, J = 12.8, 13.1 Hz, 2 H), 1.08–1.17 (m, 1 H) ppm. ^{13}C NMR (125 MHz, $CDCl_3$): δ = 174.7, 165.1 (d, J_{C-F} = 254.6 Hz), 141.4, 132.4, 123.3, 117.4, 111.6, 56.7, 54.0, 40.6, 32.1, 26.0, 25.8, 25.3 ppm. HRMS calculated for $C_{15}H_{18}FNO_4S$ $[M + H]^+$ 328.1019; found 328.1036 (TOF MS EI^+).

Methyl [2-(4-Methoxyphenyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-3-yl]acetate (13): Prepared using general method (B) using benzenesulfonyl chloride, *p*-methoxybenzylamine and methyl acrylate to produce 71 mg of **13** (84%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1735, 1514, 1292 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.85 (d, J = 7.1 Hz, 1 H), 7.51–7.59 (m, 2 H), 7.42 (d, J = 8.5 Hz, 3 H), 6.86 (d, J = 8.6 Hz, 2 H), 4.80 (t, J = 6.4 Hz, 1 H), 4.57 (d, J = 12.4 Hz, 1 H), 4.41 (d, J = 15.4 Hz, 1 H), 3.80 (s, 3 H), 3.63 (s, 3 H), 2.87 (dd, J = 16.3, 5.3 Hz, 1 H), 2.69 (dd, J = 16.3, 6.9 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.6, 159.4, 137.3, 134.8, 132.0, 130.2, 129.3, 127.0, 124.0, 121.4, 114.0, 56.6, 55.3, 46.0 ppm. HRMS calculated for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_5\text{S}$ [$\text{M} + \text{NH}_4$] $^+$ 379.1328; found 379.1337 (TOF MS EI^+).

Ethyl 3-[2-(*N*-*tert*-Butylsulfamoyl)-5-fluorophenyl]propanoate (14): Prepared using general method (A) using 4-fluoro-2-bromobenzenesulfonyl chloride, *tert*-butylamine and ethyl acrylate to afford 41 mg of **14** (48%) as a clear oil. FTIR (neat): $\tilde{\nu}$ = 1718, 1573, 1291, 1212, 1150 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 8.38 (dd, J = 15.9, 0.65 Hz, 1 H), 8.15 (dd, J = 11.2, 5.6 Hz, 1 H), 7.30 (dd, J = 9.2, 2.6 Hz, 1 H), 7.14 (ddd, J = 10.3, 7.7, 2.6 Hz, 1 H), 6.35 (d, J = 21.5 Hz, 1 H), 4.68 (s, 1 H), 4.28 (q, J = 7.1 Hz, 2 H), 1.33 (t, J = 7.1 Hz, 3 H), 1.16 (s, 9 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 165.8, 163.63, 140.1, 137.5, 136.4, 132.6, 123.7, 116.4, 114.9, 61.3, 55.1, 30.1, 14.1 ppm. HRMS calculated for $\text{C}_{15}\text{H}_{21}\text{FNO}_4\text{S}$ [MH] $^+$ 330.1175; found 330.1193 (TOF MS EI^+).

Compound 16: Prepared using general method (B) using 2,5-dibromobenzenesulfonyl chloride, *p*-methoxybenzylamine and methyl vinyl ketone to yield 86 mg of **16** (88%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1716, 1612, 1292, 1249, 1157 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.95 (s, 1 H), 7.67 (dd, J = 8.1, 1.4 Hz, 1 H), 7.51 (d, J = 16.2 Hz, 1 H), 7.34 (d, J = 8.1 Hz, 1 H), 7.30 (d, J = 6.7 Hz, 2 H), 6.62 (d, J = 11.3 Hz, 2 H), 6.77 (d, J = 10.9 Hz, 1 H), 4.94 (m, 1 H), 4.43 (d, J = 3.84 Hz, 2 H), 3.78 (s, 3 H), 2.98 (dd, J = 18.1, 5.3 Hz, 1 H), 2.78 (dd, J = 18.1, 6.7 Hz, 1 H), 2.39 (s, 3 H), 1.98 (s, 3 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 205.5, 197.8, 159.4, 140.9, 139.8, 136.1, 136.0, 132.44, 129.9, 129.0, 126.9, 125.0, 120.4, 114.1, 55.8, 55.2, 47.8, 46.7, 30.3, 28.0 ppm. HRMS calculated for $\text{C}_{22}\text{H}_{24}\text{NO}_5\text{S}$ [$\text{M} + \text{H}$] $^+$ 414.1375; found 414.1364 (TOF MS EI^+).

Methyl (2*E*)-3-[2-Octyl-3-(2-methoxy-2-oxoethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-6-yl]acrylate (17): Prepared using general method (B) using 2,5-dibromobenzenesulfonyl chloride, *p*-methoxybenzylamine and methyl acrylate to produce 86 mg of **17** (84%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 2925, 1724, 1641, 1436, 1298, 1205, 1159 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.91 (s, 1 H), 7.67–7.74 (m, 2 H), 7.46 (d, J = 8.1 Hz, 1 H), 6.51 (d, J = 16.0 Hz, 2 H), 4.92 (t, J = 5.5 Hz, 1 H), 3.81 (s, 3 H), 3.73 (s, 3 H), 3.30 (t, J = 7.5 Hz, 2 H), 2.99 (dd, J = 16.4, 5.3 Hz, 1 H), 2.77 (dd, J = 16.4, 7.1 Hz, 1 H), 1.66–1.74 (m, 2 H), 1.25–1.37 (s, 12 H), 0.86 (t, J = 5.5 Hz, 3 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.7, 166.6, 142.0, 138.9, 136.2, 136.0, 132.4, 124.8, 120.7, 120.4, 119.9, 57.4, 53.7, 51.5, 43.7, 38.8, 31.7, 29.5, 28.9, 26.4, 26.6, 14.1 ppm. HRMS calculated for $\text{C}_{22}\text{H}_{32}\text{NO}_6\text{S}$ [$\text{M} + \text{H}$] $^+$ 438.1950; found 438.1964 (TOF MS EI^+).

Methyl (2*E*)-3-[2-(4-Methoxyphenyl)-3-(2-methoxy-2-oxoethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-6-yl]acrylate (18): Prepared using general method (B) using 2,5-Dibromobenzenesulfonyl chloride, *p*-methoxybenzylamine and methyl acrylate to yield 98 mg of **18** (93%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1720, 1641, 1492, 1307, 1207, 1172, 1155 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.95 (s, 1 H), 7.65–7.69 (m, 2 H), 7.38 (d, J = 8.1 Hz, 1 H), 7.33 (d, J = 11.5 Hz, 2 H), 6.86 (d, J = 9.6 Hz, 2 H), 6.52 (d, J = 16.0 Hz, 1

H), 4.79 (dd, J = 6.9, 5.1 Hz, 1 H), 4.59 (d, J = 15.3 Hz, 1 H), 4.40 (d, J = 15.3 Hz, 1 H), 3.82 (s, 3 H), 3.79 (s, 3 H), 3.63 (s, 3 H), 2.88 (dd, J = 16.3, 5.0 Hz, 1 H), 2.70 (dd, J = 16.3, 7.0 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.3, 166.6, 159.4, 141.1, 138.7, 136.2, 135.9, 132.3, 129.9, 126.7, 124.8, 120.7, 120.2, 114.1, 56.4, 55.2, 52.1, 46.0, 38.5 ppm. HRMS calculated for $\text{C}_{22}\text{H}_{24}\text{NO}_7\text{S}$ [$\text{M} + \text{H}$] $^+$ 446.1273; found 446.1269 (TOF MS EI^+).

Ethyl (2*E*)-3-[3-(2-Ethoxy-2-oxoethyl)-2-(2-methoxybenzyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-6-yl]acrylate (19): Prepared using general method (B) using 2,5-dibromobenzenesulfonyl chloride, 2-methoxyphenylamine and ethyl acrylate to produce 107 mg of **19** (86%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 1720, 1602, 1492, 1307, 1207, 1172 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.99 (s, 1 H), 7.76 (dd, J = 8.1, 1.5 Hz, 1 H), 7.71 (d, J = 16.0 Hz, 1 H), 7.56 (d, J = 8.1 Hz, 1 H), 7.35 (d, J = 8.1 Hz, 1 H), 7.05–7.08 (m, 1 H), 7.36 (t, J = 2.2 Hz, 1 H), 6.88 (dd, J = 8.4, 2.5 Hz, 1 H), 6.53 (d, J = 16.0 Hz, 1 H), 5.56 (dd, J = 7.9, 4.1 Hz, 1 H), 4.28 (q, J = 7.9 Hz, 1 H), 4.08 (q, J = 11.4 Hz, 1 H), 3.83 (s, 3 H), 2.97 (dd, J = 16.3, 4.2 Hz, 1 H), 2.76 (dd, J = 16.4, 8.0 Hz, 1 H), 1.34 (t, J = 9.8 Hz, 1 H), 1.16 (t, J = 11.4 Hz, 1 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 170.0, 169.18, 160.6, 141.6, 137.5, 136.6, 135.5, 135.0, 134.8, 132.6, 130.8, 124.9, 121.4, 120.4, 117.4, 113.2, 111.0, 61.3, 60.9, 58.1, 55.2, 38.5, 14.2, 13.8 ppm. HRMS calculated for $\text{C}_{23}\text{H}_{26}\text{NO}_7\text{S}$ [$\text{M} + \text{H}$] $^+$ 460.1430; found 460.1442 (TOF MS EI^+).

***N*-Benzyl-2-bromobenzamide (20):** To a round-bottomed flask under Ar was added benzylamine (0.51 cm^3 , 4.66 mmol), dry DCM (0.46 M, 10 cm^3) and Et_3N (1.29 cm^3 , 9.33 mmol). The reaction was cooled to 0 $^\circ\text{C}$ and after stirring for 5 min, 2-bromobenzyl bromide (0.547 cm^3 , 4.19 mmol) was added. The reaction was warmed to r.t. and stirred for 2 h. Then the crude reaction was concentrated in situ and suspended in EtOAc (10 cm^3). The resulting suspension was filtered through a silica plug and the solvent removed to yield 1.1 g of **20** (95%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 3269, 2923, 1643, 1537, 1427, 1313 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.58 (dd, J = 8.0, 1.0 Hz, 1 H), 7.56 (dd, J = 7.6, 1.7 Hz, 1 H), 7.33–7.40 (m, 4 H), 7.31 (dt, J = 7.0, 1.5 Hz, 1 H), 7.27 (td, J = 8.1, 1.8 Hz, 2 H), 6.24 (br. s, 1 H), 4.66 (d, J = 5.7 Hz, 2 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 167.5, 137.6, 137.5, 133.4, 131.7, 129.6, 128.8, 128.0, 127.7, 127.6, 119.3, 44.2 ppm. HRMS calculated for $\text{C}_{14}\text{H}_{13}\text{BrNO}$ [$\text{M} + \text{H}$] $^+$ 290.0181; found 290.0179 (TOF MS EI^+). ^1H and ^{13}C NMR spectroscopic data corresponded to that reported by Catellani and coworkers.^[31]

***N*-(2-Bromobenzyl)-4-methylbenzenesulfonamide (21):** To a round-bottomed flask under Ar was added 2-bromobenzylamine (0.5 g, 2.68 mmol), dry DCM (0.46 M, 5.8 cm^3) and Et_3N (0.75 cm^3 , 5.36 mmol). The reaction was cooled to 0 $^\circ\text{C}$ and after stirring for 5 min, *p*-toluenesulfonyl chloride (0.51 g, 2.68 mmol) was added. The reaction was warmed to r.t. and stirred for 2 h. Then the crude reaction was concentrated in situ and suspended in EtOAc (10 cm^3). The resulting suspension was filtered through a silica plug and the solvent removed to yield 0.87 g of **21** (96%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 3282, 1467, 1326, 1159, 1093 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 7.60 (d, J = 8.2 Hz, 2 H), 7.45 (d, J = 7.9 Hz, 1 H), 7.19–7.30 (m, 4 H), 7.10 (dt, J = 9.3, 1.5 Hz, 1 H), 4.92 (m, 1 H), 4.22 (d, J = 6.5 Hz, 2 H), 2.40 (s, 3 H) ppm. ^{13}C NMR (125 MHz, CDCl_3): δ = 162.1, 143.5, 136.8, 135.4, 132.8, 130.6, 129.7, 129.6, 127.7, 127.6, 127.1, 123.5, 47.5, 21.5 ppm. ^1H and ^{13}C NMR spectroscopic data corresponded to that reported by Malacria and coworkers.^[32]

***N*-(2-Bromobenzyl)methanesulfonamide (22):** To a round-bottomed flask under Ar was added 2-bromobenzylamine (0.5 g, 2.68 mmol), dry DCM (0.46 M, 5.8 cm^3) and Et_3N (0.75 cm^3 , 5.36 mmol). The

reaction was cooled to 0 °C and after stirring for 5 min, methanesulfonyl chloride (0.22 cm³, 2.95 mmol) was added. The reaction was warmed to r.t and stirred for 2 h. Then the crude reaction was concentrated in situ and suspended in EtOAc (10 cm³). The resulting suspension was filtered through a silica plug and the solvent removed to yield 0.65 g of **22** (92%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 3284, 1440, 1319, 1149 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 7.59 (d, *J* = 7.9 Hz, 1 H), 7.45 (d, *J* = 7.6 Hz, 1 H), 7.33 (t, *J* = 7.5 Hz, 1 H), 7.21 (dt, *J* = 7.5, 1.5 Hz, 1 H), 4.90 (m, 1 H), 4.41 (d, *J* = 6.4 Hz, 2 H), 2.81 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 162.1, 135.8, 133.2, 130.7, 130.0, 128.0, 123.7, 47.63, 41.3; ¹H and ¹³C NMR spectroscopic data corresponded to that reported by Malacria and coworkers.^[32]

2-Bromo-*N*-(2-bromobenzyl)benzenesulfonamide (23): To a round-bottomed flask under Ar was added 2-bromobenzylamine (0.5 g, 2.68 mmol), dry DCM (0.46 m, 5.8 cm³) and Et₃N (0.75 cm³, 5.36 mmol). The reaction was cooled to 0 °C and after stirring for 5 min, 2-bromobenzenesulfonyl chloride (0.61 g, 2.41 mmol) was added. The reaction was warmed to r.t and stirred for 2 h. Then the crude reaction was concentrated in situ and suspended in EtOAc (10 cm³). The resulting suspension was filtered through a silica plug and the solvent removed to yield 0.90 g of **23** (93%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 3326, 1440, 1336, 1164, 1026 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 8.80 (dd, *J* = 7.8, 1.7 Hz, 1 H), 7.58 (dd, *J* = 7.8, 1.1 Hz, 1 H), 7.45 (dd, *J* = 6.9, 2.2 Hz, 1 H), 7.40 (dt, *J* = 7.7, 1.1 Hz, 1 H), 7.33 (dt, *J* = 7.6, 1.7 Hz, 1 H), 7.12 (dd, *J* = 7.7, 1.5 Hz, 1 H), 7.05–7.08 (m, 2 H), 5.79 (m, 1 H), 4.26 (d, *J* = 6.6 Hz, 2 H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 162.1, 139.1, 134.9, 133.5, 132.7, 131.4, 130.6, 129.8, 129.6, 127.6, 127.4, 123.8, 119.9, 47.7 ppm. HRMS calculated for C₁₃H₁₁Br₂NO₂SNa [M + Na]⁺ 425.8775; found 425.8781 (TOF MS EI⁺).

Methyl (E)-3-(2-({3-(2-methoxy-2-oxoethyl)-1,1-dioxido-1,2-benzisothiazol-2(3*H*)-yl)methyl}phenyl)acrylate (24): To a 1-dram vial was added **23** (76 mg, 0.19 mmol), Et₃N (79 μ L, 0.56 mmol), Bu₄NCl (70 mg, 0.19 mmol), Pd₂(dba)₃·CHCl₃ (2 mol-%, 3.9 mg, 0.0038 mmol) and dry DMF (1.89 mL). After stirring for 5 min at room temp., methyl acrylate (51 μ L, 0.56 mmol) was added and the reaction vial was placed immediately into a preheated reaction block. The reaction mixture was stirred at 110 °C for 14 h after which time the reaction was cooled and concentrated under reduced pressure. The crude was purified by column chromatography (1:1 hexane/EtOAc) to yield 59 mg of **24** (76%) as a yellow oil. FTIR (neat): $\tilde{\nu}$ = 2950, 2358, 1716, 1299, 1172, 763 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 8.10 (d, *J* = 15.7 Hz, 1 H), 7.83 (d, *J* = 7.3 Hz, 1 H), 7.61 (ddd, *J* = 7.5, 1.2 Hz, 2 H), 7.55 (ddd, *J* = 5.3, 0.7 Hz, 2 H), 7.32–7.40 (m, 3 H), 6.35 (d, *J* = 15.7 Hz, 1 H), 4.87 (t, *J* = 6.3 Hz, 1 H), 4.76 (d, *J* = 15.9 Hz, 1 H), 4.60 (d, *J* = 15.9 Hz, 1 H), 3.80 (s, 3 H), 3.54 (s, 3 H), 2.87 (dd, *J* = 16.6, 5.5 Hz, 1 H), 2.70 (dd, *J* = 16.6, 6.9 Hz, 1 H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 170.5, 166.9, 140.8, 137.2, 134.5, 134.3, 133.7, 133.3, 130.3, 129.6, 128.9, 127.1, 126.2, 124.2, 121.5, 120.9, 58.3, 52.0, 51.8, 45.0, 39.1 ppm. HRMS calculated for C₂₁H₂₁NO₆SNa [M + Na]⁺ 438.0987; found 438.0981 (TOF MS EI⁺).

General Procedure (C) for the Synthesis of 1,1-Dioxido-1,2-benzisothiazol-3-acetamide Derivatives 29–31: Into a 1-dram vial was added amine (2.73 $\times 10^{-5}$ mol), Et₃N (5.47 $\times 10^{-5}$ mol) and dry DMF (0.1 mL) were the reaction mixture was stirred at room temp. for 15 min. Then, α -bromobenzenesulfonyl chlorides (2.73 $\times 10^{-5}$ mol) were added and the reaction mixture was stirred for 2 h. Then, Et₃N (5.482.73 $\times 10^{-5}$ mol), Bu₄N (7.45 mg, 2.73 $\times 10^{-5}$ mol), Pd₂(dba)₃·CHCl₃ (2 mol-%, 2.56 mg, 0.056 $\times 10^{-5}$ mol) and dry DMF (0.14 mL) were added to the reac-

tion vial. After stirring for 5 min at room temp., acrylic acid (8.19 $\times 10^{-5}$ mol mmol) was added and the reaction vial was placed immediately into a preheated reaction block. The reaction mixture was stirred at 110 °C for 14 h after which time the reaction was cooled and concentrated. The crude was then solvated in dry DCM (0.1 mL), to which *N*-methylmorpholine (35 μ L, 4.09 $\times 10^{-5}$ mol) was added. After stirring for 5 min a solution of OACC₅₀ (17 mg, 5.46 $\times 10^{-5}$ mol) in dry DCM (0.1 mL) was added and the reaction mixture stirred for 10 h at room temp. Then, the crude was absorbed onto silica and purified by flash chromatography (hexane/EtOAc).

Compound 29: Prepared using general method (C) using benzenesulfonyl chloride, cyclopentylamine, acrylic acid and morpholine. The crude material was purified by flash chromatography (hexane/EtOAc, 1:1) to yield 5.92 mg of **30** (56%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 2956, 1637, 1458, 1298, 1170, 1114, 1041 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 7.75 (d, *J* = 8.1 Hz, 1 H), 7.54–7.57 (m, 1 H), 7.49–7.54 (m, 2 H), 5.13–5.17 (m, 1 H), 3.96 (h, *J* = 7.6 Hz, 1 H), 3.71–3.74 (m, 1 H), 3.67 (t, *J* = 4.7 Hz, 2 H), 3.54–3.58 (m, 2 H), 3.40–3.56 (m, 2 H), 3.29–3.33 (m, 1 H), 3.04 (dd, *J* = 15.3, 5.4 Hz, 1 H), 2.71 (dd, *J* = 15.3, 7.9 Hz, 1 H), 2.02–2.08 (m, 1 H), 1.91–1.96 (m, 1 H), 1.71–1.78 (m, 2 H), 1.56–1.68 (m, 4 H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 168.4, 139.6, 136.3, 132.8, 129.3, 124.8, 121.0, 66.7, 58.4, 57.1, 46.2, 42.1, 38.8, 30.8, 28.3, 23.4, 22.8 ppm. HRMS calculated for C₁₈H₂₄N₂O₄SNa [M + Na]⁺ 387.1354; found 387.1354 (TOF MS EI⁺).

Compound 30: Prepared using general method (C) using benzenesulfonyl chloride, cyclohexylamine, acrylic acid and pyridin-3-amine. The crude material was purified by flash chromatography (EtOAc) to yield 4.3 mg of **31** (43%) as a off white solid. FTIR (neat): $\tilde{\nu}$ = 2933, 2360, 1683, 1683, 1292, 1170 cm⁻¹. ¹H NMR (500 MHz, MeOD): δ = 8.74 (s, 1 H), 8.28 (d, *J* = 3.2 Hz, 1 H), 8.12 (dt, *J* = 8.4, 1.5 Hz, 1 H), 7.73 (d, *J* = 7.7 Hz, 1 H), 7.64 (dt, *J* = 7.6, 1.0 Hz, 1 H), 7.57 (t, *J* = 7.5 Hz, 1 H), 7.54 (t, *J* = 7.5 Hz, 1 H), 7.41 (dd, *J* = 8.3, 4.8 Hz, 1 H), 5.26 (t, *J* = 6.6 Hz, 1 H), 3.57 (tt, *J* = 11.8, 3.6 Hz, 1 H), 3.07 (dd, *J* = 14.9, 6.1 Hz, 1 H), 3.07 (dd, *J* = 14.9, 6.1 Hz, 1 H), 2.85 (dd, *J* = 14.9, 7.1 Hz, 1 H), 1.97 (d, *J* = 12.6 Hz, 1 H), 1.90 (d, *J* = 12.3 Hz, 1 H), 1.69–1.83 (m, 4 H), 1.63 (d, *J* = 12.7 Hz, 1 H), 1.23–1.37 (m, 2 H), 1.18 (tt, *J* = 12.7, 2.9 Hz, 1 H) ppm. ¹³C NMR (125 MHz, MeOD): δ = 171.0, 165.2 (d, *J*_{C-F} = 254.1 Hz), 145.6, 142.0, 140.4, 137.8, 134.3, 130.8, 129.2, 125.8, 121.7, 58.7, 57.4, 44.9, 32.8, 31.4, 27.3, 27.2, 26.6 ppm. HRMS calculated for C₂₀H₂₄N₃O₃SNa [M + H]⁺ 386.1538; found 386.1547 (TOF MS EI⁺).

Compound 31: Prepared using general method (C) using 4-fluorobenzenesulfonyl chloride, 4-methoxybenzylamine, acrylic acid and piperidine. The crude material was purified by flash chromatography (hexane/EtOAc, 1:1) to yield 6.46 mg of **32** (52%) as a white solid. FTIR (neat): $\tilde{\nu}$ = 2937, 1635, 1514, 1296, 1247, 1174 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 7.79 (dd, *J* = 8.4, 4.7 Hz, 1 H), 7.33 (d, *J* = 8.6 Hz, 2 H), 7.21 (d, *J* = 8.6 Hz, 2 H), 6.85 (d, *J* = 8.7 Hz, 2 H), 5.06 (dd, *J* = 7.8, 5.0 Hz, 1 H), 4.47 (d, *J* = 3.7 Hz, 2 H), 3.65 (s, 3 H), 3.47–3.58 (m, 2 H), 3.11–3.21 (m, 2 H), 2.81 (dd, *J* = 16.2, 5.0 Hz, 1 H), 2.57 (dd, *J* = 16.2, 7.9 Hz, 1 H), 1.57–1.62 (m, 2 H), 1.48–1.54 (m, 2 H), 1.34–1.42 (m, 2 H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 167.1, 165.2 (d, *J*_{C-F} = 2.1 Hz), 159.39, 131.0, 130.0, 127.3, 123.4, 123.3, 117.2, 117.0, 114.2, 112.7, 112.5, 55.3, 47.0, 46.5, 42.9, 38.2, 26.2, 25.5, 24.3 ppm. HRMS calculated for C₂₂H₂₅FN₂O₄SNa [M + Na]⁺ 455.1417; found 455.1422 (TOF MS EI⁺).

Supporting Information (see also the footnote on the first page of this article): Copies of NMR spectra.

Acknowledgments

This work was generously supported by funds provided by the National Institutes of Health (NIH), Center for Chemical Methodologies and Library Development at the University of Kansas (KU-CMLD) (P50 GM069663), Pilot Scale Libraries Program (P41 GM076302) and NIH COBRE award (P20 RR015563). Undergraduate funding was provided via an NIH K-INBRE award (P20 R016475) (to K. Y.) and the KU Center of Research (to K. Y.).

- [1] For reviews on domino processes, see: a) A. Padwa, S. K. Bur, *Tetrahedron* **2007**, *63*, 5341–5378; b) D. Enders, C. Grondal, M. R. M. Hüttl, *Angew. Chem. Int. Ed.* **2007**, *46*, 1570–1581; c) L. F. Tietze, *Chem. Rev.* **1996**, *96*, 115–136; d) L. F. Tietze, U. Beifuss, *Angew. Chem. Int. Ed. Engl.* **1993**, *32*, 131–163.
- [2] A domino reaction is defined by Tietze as a “transformation of two or more bond-forming reactions under identical reaction conditions, in which the latter transformations take place at the functionalities obtained in the former bond forming reactions.” *Domino Reactions in Organic Synthesis* (Eds.: L. F. Tietze, G. Brasche, K. M. Gericke), Wiley-VCH, Weinheim, Germany, **2006**.
- [3] a) S. Fustero, D. Jiménez, M. Sánchez-Roselló, C. del Pozo, *J. Am. Chem. Soc.* **2007**, *129*, 6700–6701; b) H.-P. Bi, X.-Y. Liu, F.-R. Gou, L.-N. Guo, X.-H. Duan, X.-Z. Shu, Y.-M. Liang, *Angew. Chem. Int. Ed.* **2007**, *46*, 7068–7071; c) X. Gai, R. Grigg, T. Khamnaen, S. Rajviroongit, V. Sridharan, L. Zhang, S. Collard, A. Keep, *Tetrahedron Lett.* **2003**, *44*, 7441–7443; d) Y. Zeng, D. S. Reddy, E. Hirt, J. Aubé, *Org. Lett.* **2004**, *6*, 4993–4995; e) S. Kirschbaum, H. Waldmann, *Tetrahedron Lett.* **1997**, *38*, 2829–2832.
- [4] a) M. Bandini, A. Eichholzer, M. Monari, F. Piccinelli, A. Umami-Romcho, *Eur. J. Org. Chem.* **2007**, *18*, 2917–2920; b) D. Perdicchia, K. A. Jørgensen, *J. Org. Chem.* **2007**, *72*, 3565–3568; c) G. Balme, N. Bouyssi, *Metal-catalyzed cascade reactions* (Ed.: T. J. J. Müller), *Topics in Organometallic Chemistry*, Springer Verlag, Berlin, **2006**, vol. 19, pp. 115–149.
- [5] a) N. Barr, J. P. Bartley, P. W. Clark, P. Dyke, S. F. Dunstan, *J. Organomet. Chem.* **1986**, *302*, 117; b) G. Dyker, P. Grundt, *Tetrahedron Lett.* **1996**, *37*, 619–622; c) Md. W. Khan, A. F. G. M. Reza, *Tetrahedron* **2005**, *61*, 11204–11210.
- [6] B. K. Rao, G. H. Hamor, *Pharm. Sci.* **1969**, 628–630.
- [7] a) J. Drews, *Science* **2000**, *287*, 1960–1964; b) A. Scozzafava, T. Owa, A. Mastrolorenzo, C. T. Supuran, *Curr. Med. Chem.* **2003**, *10*, 925–953.
- [8] L. Levy, *Drugs Future* **1992**, *17*, 451–454.
- [9] C. Valente, R. C. Guedes, R. Moreira, J. Iley, J. Gut, P. J. Rosenthal, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4115–4119.
- [10] L. Zhuang, J. S. Wai, M. W. Embrey, T. E. Fisher, M. S. Egbertson, L. S. Payne, J. P. Guare Jr., J. P. Vacca, D. J. Hazuda, P. J. Felock, A. L. Wolfe, K. A. Stillmock, M. V. Witmer, G. Moyer, W. A. Schleif, L. J. Gabryelski, Y. M. Leonard, J. J. Lynch Jr., S. R. Michelson, S. D. Young, *J. Med. Chem.* **2003**, *46*, 453–456.
- [11] Y. Misu, H. Togo, *Org. Biomol. Chem.* **2003**, *1*, 1342–1346.
- [12] a) R. D. Bravo, A. A. Canepa, *Synth. Commun.* **2002**, *32*, 3675–3680; b) O. O. Orazi, R. A. Corral, R. Bravo, *Heteroat. Chem.* **1986**, *23*, 1701–1708; c) A. R. Katritzky, J. Wu, S. Rachwal, B. Rachwal, D. W. Macomber, T. P. Smith, *Org. Prep. Proced. Int.* **1992**, *24*, 463–467.
- [13] J. Lee, Y.-L. Zhong, R. A. Reamer, D. Askin, *Org. Lett.* **2003**, *5*, 4175–4177.
- [14] U. Chiacchio, A. Corsaro, A. Rescifina, M. Bkaithan, G. Grassi, A. Piperno, T. Privitera, T. G. Romeo, *Tetrahedron* **2001**, *57*, 3425–3433.
- [15] a) P. Metz, D. Seng, R. Fröhlich, *Synlett* **1996**, 741–742; b) B. Plietker, D. Seng, R. Fröhlich, P. Metz, *Tetrahedron* **2000**, *56*, 873–879; c) V. O. Rogatchov, H. Bernsmann, P. Schwab, R. Fröhlich, B. Wibbeling, P. Metz, *Tetrahedron Lett.* **2002**, *43*, 4753–4756; d) I. R. Greig, M. J. Tozer, P. T. Wright, *Org. Lett.* **2001**, *3*, 369–371.
- [16] a) M. D. McReynolds, J. M. Dougherty, P. R. Hanson, *Chem. Rev.* **2004**, *104*, 2239–2258; b) J.-M. Moriggi, L. J. Brown, J. L. Castro, R. C. D. Brown, *Org. Biomol. Chem.* **2004**, *2*, 835–844; c) D. Freitag, P. Schwab, P. Metz, *Tetrahedron Lett.* **2004**, *45*, 3589–3592; d) S. Karsch, D. Freitag, P. Schwab, P. Metz, *Synthesis* **2004**, *10*, 1696–1712; e) M. Jiménez-Hopkins, P. R. Hanson, *Org. Lett.* **2008**, *10*, 2223–2226.
- [17] a) S. Merten, R. Fröhlich, O. Kataeva, P. Metz, *Adv. Synth. Catal.* **2005**, *347*, 754–758; b) A. Vasudevan, P. S. Tseng, S. W. Djuric, *Tetrahedron Lett.* **2006**, *47*, 8591–8593; c) L. A. Paquette, R. D. Dura, N. Fosnaugh, S. Marshall, *J. Org. Chem.* **2006**, *71*, 8438–8445; d) L. A. Paquette, W. R. S. Barton, J. C. Gallucci, *Org. Lett.* **2004**, *6*, 1313–1315.
- [18] X.-Y. Liu, C.-H. Li, C.-M. Che, *Org. Lett.* **2006**, *8*, 2707–2710.
- [19] a) P. Dauban, R. H. Dodd, *Org. Lett.* **2000**, *2*, 2327–2329; b) P. Dauban, L. Sanière, A. Tarrade, R. H. Dodd, *J. Am. Chem. Soc.* **2001**, *123*, 7707–7708; c) E. S. Sherman, S. R. Chemler, T. B. Tan, O. Gerlits, *Org. Lett.* **2004**, *6*, 1573–1575; d) W. Zeng, S. R. Chemler, *J. Am. Chem. Soc.* **2007**, *129*, 12948–12949.
- [20] a) J.-L. Liang, S.-X. Yuan, P. W. H. Chan, C.-M. Che, *Org. Lett.* **2002**, *4*, 4507–4510; b) A. Padwa, A. C. Flick, C. A. Levrett, T. Stengel, *J. Org. Chem.* **2004**, *69*, 6377–6386.
- [21] A. Zhou, P. R. Hanson, *Org. Lett.* **2008**, *10*, 2551–2554.
- [22] Sulfonamide **1** was submitted to the one pot conditions at room temp. without Pd₂(dba)₃·CHCl₃, giving the aza-Michael adduct after 2 hours.
- [23] a) L. Artok, H. Bulut, *Tetrahedron Lett.* **2004**, *45*, 3881–3884; b) L. Botella, C. Najera, *Tetrahedron Lett.* **2004**, *45*, 1833–1836; c) I. D. Gittins, F. Caruso, *Angew. Chem. Int. Ed.* **2001**, *40*, 3001–3004.
- [24] Workup consisted of removal of DMF, suspension of the crude reaction mixture in EtOAc and filtration through a SiO₂ SPE to remove Pd and organic salts.
- [25] It is worth noting that in a limited number of cases the acyclic intermediate resulting from the Heck reaction was observed in the crude mixture in small quantities (**14**: R¹ = H, R² = *t*Bu, R³ = OMe); experimental data for **14** is provided.
- [26] As previously noted in the introductory paragraph, it has been reported that this reaction does proceed but requires days and ultimately gave low yield unless the iodobenzamides were utilized instead of the aryl bromides.
- [27] a) N. Kanamitsu, T. Osaki, Y. Itsuji, M. Yoshimura, H. Tsujimoto, M. Soga, *Chem. Pharm. Bull.* **2007**, *55*, 1682–1688; b) J. Dudash, P. Rybczynski, M. Urbanski, A. Xiang, R. Zeck, X. Zhang, Y. Zhang, *U. S. Pat. Appl. Publ.* **2007**, p. 65; c) G. Schubert, J. Rieke-Keil, J. Zapp, H.-W. Kleemann, R. Hanna, B.-G. Huang, X.-D. Wu, Y. Gourand, *U. S. Pat. Appl. Publ.* **2005**, p. 24.
- [28] M. Zhang, P. Vedantham, D. L. Flynn, P. R. Hanson, *J. Org. Chem.* **2004**, *69*, 8340–8344.
- [29] Attempts to develop a “true” one-pot process starting from the corresponding sulfonamide were investigated. However it was discovered that lowering the equivalents of acrylic acid from 3 to 1–1.5 significantly reduced the amount of cyclic acid formed and hence the amount of corresponding amide isolated.
- [30] R. H. Grubbs, R. K. Rosen, F. J. Timmers, *Organometallics* **1996**, *15*, 1518–1520.
- [31] R. Ferraccioli, D. Carenzi, O. Rombola, M. Catellani, *Org. Lett.* **2004**, *6*, 4759–4762.
- [32] F. Marion, J. Coulomb, A. Servais, C. Courillon, L. Fensterbank, M. Malacria, *Tetrahedron* **2006**, *62*, 3856–3871.

Received: July 2, 2008

Published Online: September 22, 2008